Compare Nuscale Power Corporation (SMR) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs Tempus AI — how do they compare? Nuscale Power Corporation trades at $10.84 (market cap $4.59B), while Tempus AI trades at $61.16 (market cap $11.67B). The key difference: Tempus AI is far larger — about 2.5× Nuscale Power Corporation's market cap, and Tempus AI is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| SMR | TEM | |
|---|---|---|
Market Cap | $4.59B | $11.67B |
Sector | Utilities | Broad Market / Factor |
52-Week High | $53.43 | $103.25 |
52-Week Low | $7.59 | $41.55 |
Enterprise Value | $3.52B | $12.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMR stock surged 15.32% to $11.18, showing strong bullish momentum with technical indicators supporting the uptrend. The company maintains a substantial cash position of $1.9 billion despite significant operating losses and negative profit margins. Recent news highlights NuScale's positioning in the nuclear energy sector, particularly for AI power demands, though the company remains years away from commercial deployment.
The outlook remains speculative with Wall Street divided - 50% of analysts recommend Buy with a $11.25 consensus target. Key risks include cash burn acceleration, lack of firm commercial contracts, and execution challenges in bringing small modular reactors to market. The stock offers high-risk/high-reward potential for investors betting on nuclear energy adoption.
Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats despite negative profitability, with a P/S of 7.99 and P/B of 26.23. Recent catalysts include FDA clearance for an AI ECG product and a $9.5 million ARPA-H award for autonomous AI in cardiology (Business Wire, September 9, 2026).
Outlook remains positive given analyst consensus and growth in precision medicine, but risks include sustained losses, high valuation multiples, and cash burn. The consensus price target is $69.11, implying potential upside, though investors must weigh the company's unprofitability against its innovation pipeline and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
